Marshall Wace
PRAX icon

Marshall Wace’s Praxis Precision Medicines PRAX Stock Holding History

Marshall Wace’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.9M Buy
137,008
+91,859
+203% +$29.1M 0.04% 407
2026
Q1 		$14.5M Sell
45,149
-24,093
-35% -$7.45M 0.01% 815
2025
Q4 		$20.4M Buy
69,242
+1,101
+2% +$205K 0.02% 621
2025
Q3 		$3.61M Buy
+68,141
New +$3.3M ﹤0.01% 1333
2025
Q1 		– Sell
-58,305
Closed -$4.49M – 2999
2024
Q4 		$4.49M Sell
58,305
-111,790
-66% -$8.09M 0.01% 1107
2024
Q3 		$9.79M Sell
170,095
-78,286
-32% -$4.23M 0.01% 772
2024
Q2 		$10.3M Buy
248,381
+127,357
+105% +$6.02M 0.01% 714
2024
Q1 		$7.38M Buy
121,024
+72,182
+148% +$3.24M 0.01% 855
2023
Q4 		$1.09M Buy
48,842
+7,064
+17% +$127K ﹤0.01% 1446
2023
Q3 		$1.07M Buy
+41,778
New +$790K ﹤0.01% 1475
2023
Q2 		– Sell
-18,913
Closed -$230K – 2882
2023
Q1 		$230K Buy
+18,913
New +$798K ﹤0.01% 2376
2022
Q1 		– Sell
-1,072
Closed -$316K – 3878
2021
Q4 		$316K Sell
1,072
-12,349
-92% -$3.62M ﹤0.01% 3013
2021
Q3 		$3.72M Buy
13,421
+832
+7% +$226K 0.02% 1135
2021
Q2 		$3.45M Buy
+12,589
New +$4.51M 0.02% 1054

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Marshall Wace's PRAX Position: Q2 2026 in Review

Marshall Wace increased its Praxis Precision Medicines (PRAX) stake by 203% in Q2 2026, buying an estimated $29.1M and bringing the position to 137,008 shares worth $45.9M. The position accounts for 0.04% of the portfolio, ranked #407.

Marshall Wace first reported a position in PRAX in Q2 2021 and has held it in 14 quarters since. 310 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Marshall Wace held 137,008 shares of Praxis Precision Medicines worth $45.9M as of Q2 2026.
  • Marshall Wace bought 91,859 Praxis Precision Medicines shares in Q2 2026, an estimated $29.1M.
  • Praxis Precision Medicines made up 0.04% of Marshall Wace's portfolio in Q2 2026, its #407 holding.
  • Marshall Wace first reported a position in Praxis Precision Medicines in Q2 2021 and has held it in 14 quarters since.
  • 310 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.